High concentration of dopamine treatment may induce acceleration of human sperm motility

Hiroki Kanno¹,² | Shouhei Kurata¹ | Yuuki Hiradate³ | Kenshiro Hara¹ | Hiroaki Yoshida² | Kentaro Tanemura¹

¹Laboratory of Animal Reproduction and Development, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan
²Sendai ART Clinic, Sendai, Japan
³Research Institute for Microbial Diseases, Osaka University, Suita, Japan

Correspondence
Kentaro Tanemura, Laboratory of Animal Reproduction and Development, Graduate School of Agricultural Science, Tohoku University, 468-1, Aramaki-Aoba, Aoba-ku, Sendai, Miyagi, 980-8572, Japan.
Email: kentaro.tanemura.e4@tohoku.ac.jp

Abstract
Purpose: In humans, catecholamines (including dopamine) have been identified in semen and fallopian tubes, while dopamine D2 receptors (D2DR) are found in the sperm midpiece region. How dopamine dose affects human sperm function and whether dopamine treatment is useful in assisted reproductive technology is unclear.

Methods: Sperm samples were obtained from patients with normal semen parameters undergoing fertility treatment. We investigated the effects of dopamine treatment on tyrosine phosphorylation and sperm motility. Sperm motility was analyzed using the computer-assisted sperm analysis (CASA) system.

Results: This study revealed that various dopamine concentrations (0.1–100 μM) did not increase sperm tyrosine phosphorylation. Progressive motility increased substantially when treated with high concentrations of dopamine (10 and 100 μM) and was blocked by raclopride (a D2DR antagonist). After 24-h sperm culture, the addition of 10 μM dopamine significantly increased curvilinear velocity and amplitude of lateral head displacement, which are indicators of hyperactivation.

Conclusion: Dopamine did not affect tyrosine phosphorylation, but increased sperm motility. High concentrations of dopamine were more effective to accelerate sperm motility in cases where sperm motile capacity was low.

KEYWORDS
dopamine, dopamine receptor, neurotransmitter agents, sperm motility, spermatozoa

1 | INTRODUCTION

Male infertility constitutes 50% of infertility cases,¹-³ with defective sperm function being the most common cause. Male infertility is diagnosed using the semen analysis parameters defined by the World Health Organization.⁴ Sperm motility is a vital factor in achieving pregnancy. In vivo fertilization requires sperm to travel through the cervix, uterus, and oviduct to reach the ampulla of the fallopian tubes where it fertilizes the oocyte. In case of asthenozoospermia, the sperm cannot reach the fertilization point,⁵ resulting in infertility. During conventional in vitro fertilization (cIVF), the sperm can easily reach the oocyte surrounded by the cumulus cells. Intracytoplasmic sperm injection (ICSI) is an artificial reproductive technology that is an effective method to overcome male infertility. It has been reported that in cases of asthenozoospermia, the fertilization rate is lower through cIVF than through ICSI.⁶ Therefore,
the infertile sperm may have decreased fertilization functions such as capacitation, hyperactivation, and acrosome reaction. Moreover, ICSI has been reported to reduce embryo quality compared with cIVF.\textsuperscript{7–9} In male infertility treatment, cIVF is an important option for improved embryo quality. Therefore, activating sperm function is essential to increase the probability of pregnancy through either natural conception or infertility treatment.

Ejaculated mammalian sperm acquire capacitation ability through numerous factors when migrating through the female reproductive tract:\textsuperscript{10} When sperm reaches the ampulla of the fallopian tube, an acrosome reaction is induced, leading to fertilization. A previous study demonstrated that it was possible to induce capacitation in vitro.\textsuperscript{11} These methods are currently being used worldwide in assisted reproductive technology for successful in vitro fertilization. Both mammalian ejaculated and injected sperm are exposed to various factors such as hormones, enzymes, and ions in the uterus,\textsuperscript{12} some of which can induce capacitation by interacting with specific receptors. Interestingly, it has been reported that mammalian sperm carries neurotransmitter receptors generally found in the central nervous system. These receptors can modulate sperm function in many species.\textsuperscript{13–17}

Dopamine, the predominant neurotransmitter in the mammalian central nervous system, regulates various functions, including cognition, emotion, and endocrine function. Dysfunctional dopamine systems are associated with neurological and psychiatric disorders, including Parkinson’s disease and schizophrenia.\textsuperscript{18} Dopamine receptors are G-protein-coupled receptors and can be further divided into five subtypes (D1–D5) based on their pharmacology, biochemistry, and anatomic distribution.\textsuperscript{19} These dopamine receptor subtypes are of two categories: dopamine type 1 (D1)-like receptors and dopamine type 2 (D2)-like receptors. Stimulation of the D1-like receptors (D1DR and D5DR) activates adenyl cyclase (AC) and increases cyclic adenosine 3',5'-monophosphate (cAMP) accumulation,\textsuperscript{20} whereas stimulation of the D2-like receptors (D2DR, D3DR, and D4DR) inhibits AC activation.\textsuperscript{21} D2-like receptors such as D2DR have been reported to modulate intracellular calcium levels by triggering the release of intracellular calcium stores or by acting on ion channels.\textsuperscript{21}

It has been reported that D2DR is expressed in the sperm of many species, including humans, mice, rats, bulls, and boars.\textsuperscript{22,23} In boar sperm, stimulation of D2DR elevates tyrosine phosphorylation and accelerates sperm motility.\textsuperscript{23} Recently, it has been reported that dopamine increases some human sperm functions, such as motility parameters and the acrosome reaction, and these effects are considered to be induced by tyrosine phosphorylation.\textsuperscript{24} However, whether dopamine treatment has a positive effect on sperm tyrosine phosphorylation and how dopamine induces human sperm function are currently unknown. In addition, whether dopamine treatment is useful in assisted reproductive technology, particularly for male infertility, has not been tested. Therefore, in this study, we investigated the in vitro effect of dopamine on tyrosine phosphorylation and dopamine treatment to infertile patients useful for improve sperm motility.

# MATERIALS AND METHODS

## 2.1 Human sperm preparation

Human sperm samples were obtained from 37 normozoospermic patients between the ages of 28 and 47 years old from an infertility clinic (Sendai ART Clinic, Miyagi, Japan). Samples consisted surplus sperm that had not been used for assisted reproductive technologies. All procedures in this study were approved by the Ethics Committee of Tohoku University (Miyagi, Japan) and the Sendai ART Clinic. Informed consent was acquired from all the sample donors. Human semen was collected with masturbation after 2–7 days of sexual abstinence. After 20 min of liquefaction treatment, semen analysis was performed, and normozoospermic patient semen samples were selected according to the World Health Organization criteria (sperm concentration > 15 million/ml, sperm motility > 40%, sperm morphology > 4%).\textsuperscript{4} Motile sperm samples were prepared using density gradient centrifugation methods. The semen was briefly applied to 5 ml Gradient\textsuperscript{TM}90 (CooperSurgical), a single-layer density gradient liquid, and was centrifuged at 292×g for 20 min at room temperature (RT, 20–25°C). After discarding the supernatant, the sediment was resuspended in Sperm Wash (CooperSurgical) and washed twice. The sperm suspension was used for further experiments.

## 2.2 Western blot

The sperm samples from three patients were washed with saline and prepared at a concentration of 120–125×10\textsuperscript{6} cells/ml. Samples of mouse brain and mouse sperm were used as positive controls. C57BL/6N mice were purchased from Japan SLC (Shizuoka, Japan). Mouse brains were additional processed for adequate protein extraction with the following treatments. Radioimmunoprecipitation buffer (50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 1% protease inhibitor; Nacalai Tesque) was added to the mouse brain samples followed by sonication to extract proteins. The mouse brain samples were then centrifuged (7938×g, 5 min, 4°C) and the supernatant was collected. Equal volumes of 2× sample buffer (Nacalai Tesque) was added to each of the human sperm, mouse brain, and sperm, and the extracted samples were subjected to heat shock at 100°C for 5 min. The proteins were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 1% bovine serum albumin (BSA, Merck KGaA) in Tris-buffered saline containing 0.1% Tween 20 (TBS-T, pH 7.5–7.8) for 30 min at RT. After being washed three times with TBS-T, the membranes were incubated (overnight at 4°C) with mouse monoclonal anti-D2DR antibody (sc-5303,1:200; Santa Cruz Biotechnology), and washed three times with TBS-T. The membranes were incubated for 2 h at RT with horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody (1:2000; Promega). After three washes with TBS-T, the membranes were treated with Chemilumino-One (Nacalai Tesque), and images were obtained using the LAS-3000-mini Lumino Image Analyzer (Fujifilm).
2.3 | Immunocytochemistry

Immunocytochemistry was performed to investigate D2DR localization in human sperm. The sperm samples from three patients were added to 2 ml phosphate-buffered saline (PBS, pH 7.4), and the suspension was collected after centrifugation (1500×g for 5 min at RT). The sperm were mixed with 10% formaldehyde (Nacalai Tesque) for 15 min at 4°C, washed with PBS, and stored at 4°C. The sperm samples were collected by centrifugation (3890×g for 5 min at 4°C) and permeabilized with 1% Triton X-100 in PBS for 15 min at 4°C. They were washed twice with PBS and blocked with 1% BSA in PBS for 60 min at 4°C. The sperm were incubated with mouse monoclonal anti-D2DR antibody (1:50) overnight at 4°C. After three washes with PBS, the sperm were incubated (1 h at RT) with Alexa Fluor 568-conjugated anti-mouse IgG (1:200; Thermo Fisher Scientific), MitoTracker® Red CMXRos (250 nM, Thermo Fisher Scientific), and Hoechst 33342 (1:2000; Thermo Fisher Scientific). Treated samples with PBS, the sperm were incubated (1 h at RT) with Alexa Fluor 488 conjugated anti-D2DR antibody (1:50) overnight at 4°C. After three washes with PBS and mounted on glass slides, and covered with coverslips. Images were obtained using an FV3000 confocal laser scanning microscope (Olympus).

2.4 | Tyrosine phosphorylation

The sperm samples from eight patients were washed by centrifugation (1168×g for 5 min) with 2 ml saline and were prepared at a concentration of 10–15×10^6 cells/ml in 5% Human Serum Albumin (HSA, Vitrolife) in Quinn’s Fertilization medium (QF, CooperSurgical). The suspensions (200μl) were divided into 1.5-ml microtubes. Saline (control) or dopamine (Merck KGaA) dissolved in saline to final concentrations of 0.1, 1, 10, and 100μM was added to the suspensions from each patient, and the suspensions were cultured (3 h at 37°C) in 6% CO₂ and air. After incubation, the suspensions were collected by centrifugation (1500×g for 5 min) and were resuspended in 50μl saline. The same volume of 2× sample buffer was added to the suspensions, heated at 100°C for 5 min, and stored at −80°C. The acquired proteins were separated by 8% SDS-PAGE and transferred to polyvinylidene difluoride membranes. After 30 min of blocking with 1% BSA in TBS-T, the membrane was incubated overnight at 4°C with anti-phosphotyrosine 4G10 antibody (05–321, 1:2000; Merck KGaA) or anti-α-tubulin (sc-32293, 1:20000; Santa Cruz Biotechnology) as an internal control. After three washes with TBS-T, the membrane was treated with HRP-conjugated anti-mouse IgG (1:2000; Promega) for 2 h at RT. The membranes were reacted with Chemilumi-One, and images were obtained using the LAS-3000-mini Lumino Image Analyzer. Densitometric analyses were performed on the regions containing 81 to 105 kDa using the Image Gauge v4.22 analysis software (Fujifilm).

2.5 | Sperm motility assay

The sperm samples were washed by centrifugation (1168×g for 5 min) with saline. Suspensions from each patient were prepared at a concentration of 10–15×10^6 cells/ml using 5% HSA in QF and were divided into 200μl aliquots. The suspensions from eleven patients were treated with dopamine dissolved in saline, to a final concentration of 0.1, 1, 10, and 100μM. The other suspensions from nine patients were treated with dopamine (10 μM) in the presence or absence of raclopride (Merck KGaA), a D2DR antagonist, dissolved in saline. The concentration of raclopride added was 32nM, which is the 50% inhibition concentration (IC50). In both examinations, saline was added to the suspensions as a control. After the samples were cultured for 1 h at 37°C in 6% CO₂ and air, 20μl of the samples was analyzed once using a computer-assisted sperm analysis (CASA) system (LensHooke).

Next, to examine whether reduced sperm motility could be improved with dopamine, we added dopamine to 24-h cultures of the sperm samples. The sperm samples from each of 10 patients were similarly washed and were prepared at a concentration of 10–15×10^6 cells/ml. The suspensions were divided into 200μl aliquots and were cultured at 37°C in 6% CO₂ and air for 24 h. Dopamine solution was added to a final concentration of 10 μM, and the suspensions were cultured for 1 h at 37°C in 6% CO₂ and air. The suspensions were then analyzed once using the CASA system (LensHooke). Also, after 24-h culture, we recorded videos before and after dopamine treatment by using RI Viewer (CooperSurgical).

The parameters for sperm motility evaluation were as follows: total motility (%); progressive motility (%); average path velocity (VAP, μm/s); curvilinear velocity (VCL, μm/s); straight line velocity (VSL, μm/s); linearity (LIN = [VSL/VCL]×100, %); straightness (STR = [VSL/VAP]×100, %); amplitude of lateral head displacement (ALH, μm); wobble (WOB = [VAP/VCL]×100, %); and beat cross frequency (Hz).

2.6 | Statistical analysis

All evaluations were performed on at least three independent samples. Data are presented as mean (±SD) or medians (interquartile range). Statistical analyses were performed using the Kruskal–Wallis test, Steel test, and Wilcoxon signed-rank test. A p-value <0.05 was considered to indicate significant differences (*p < 0.05).

3 | RESULTS

3.1 | Expression pattern of D2DR in sperm

Western blot and immunofluorescent staining were performed to determine the expression and localization of D2DR in human sperm. In Western blot analysis, a specific band at approximately 51kDa (Figure 1A) was detected, similar to the mouse brain and sperm samples (positive control). This corresponds to the molecular size of D2DR at 48/51kDa. Immunoreactivity of D2DR was observed in the midpiece of human sperm (Figure 1B).
3.2 | Effect of dopamine on sperm protein tyrosine phosphorylation

Whether dopamine induces tyrosine phosphorylation of sperm proteins is an indicator of sperm capacitation. Human sperm were incubated with various dopamine concentrations (0–100 μM) for 3 h and were analyzed using Western blot (Figure 2). Acetylated α-tubulin was used as the internal control and was detected in the same band region for all groups. The regions containing the major bands for human sperm tyrosine phosphorylation (81 to 105 kDa) were analyzed. There was no significant difference between the intensity of the bands.

3.3 | Effect of dopamine on sperm motility

The effect of dopamine treatment on sperm motility, which is essential for fertilization, was evaluated. Progressive sperm motility increased significantly in samples incubated for 1 h with 10 and 100 μM dopamine (Table 1). Moreover, when coculturing dopamine and raclopride (D2DR antagonist), progressive motility was not significantly different from that of the control (Table 2). Similarly, after the suspension (24-h culture) was treated with 10 μM of dopamine for 1 h, progressive sperm motility was observed, but this was not significantly different. Furthermore, after a 24-h incubation, increased VCL and ALH were observed, which was significantly
different to the control and treatment with 10 μM dopamine for 1 h (Table 3). In some cases, dopamine treatment after 24-h incubation substantially increased motility (Movies S1 and S2).

4 | DISCUSSION

In this study, we detected coincident protein bands in human sperm, mouse sperm, and brain tissue using Western blot, corresponding with a previous study.22 The expression of D2DR was detected in the midpiece region of human sperm (Figure 1B), which is consistent with previous reports on the sperm of humans and other species such as rats, mice, bulls, and boars.22,23 The sperm midpiece is an essential region for oxidative metabolism and for promoting sperm motility. Thus, we hypothesized that dopamine could act to promote capacitation through increasing sperm motility. Two experiments were conducted to assess the effect of dopamine on human sperm function with bicarbonate and HSA, which are used to treat infertility.

First, we investigated the tyrosine phosphorylation of sperm proteins, which showed no significant difference when treated with various concentrations of dopamine (Figure 2). Tyrosine phosphorylation is one of the indicators of sperm capacitation.25,26 It has been reported that cAMP elevation and subsequent protein kinase A activation is necessary for tyrosine phosphorylation in the sperm.25 D2DR (Gαi/o family of G-proteins) and dopamine-binding of D2DR inhibit AC activity following cAMP synthesis.18,27 Therefore, dopamine in human sperm was predicted to decrease the level of tyrosine phosphorylation. However, tyrosine phosphorylation was unaffected by dopamine treatment. Mammalian sperm contains soluble adenylate cyclase (sAC), not coupled to G-protein, which is a distinct form of membrane-cyclase and is a major component of cAMP
reflected in the motility parameters (increased VCL and ALH, and shifted to hyperactivated motility, the flagellar bend and beat pattern with a high dopamine concentration (Table 3). When sperm movement is shifted to hyperactivated motility, the flagellar bend and beat patterns become asymmetric and acquire a higher amplitude. This is reflected in the motility parameters (increased VCL and ALH, and decreased LIN) estimated using the CASA system. Actually, some sperm movements were observed to be hyperactivation after culture for 24 h and treated dopamine (S2). Therefore, dopamine may have induced sperm hyperactivation but may have had a low impact in normozoospermia under culture conditions of infertility treatment. Because treatment with a high concentration of dopamine in sperm with decreased motility was more effective in improving sperm motility, we believed that male infertility may benefit from a high concentration of dopamine.

Flagella are crucial in sperm motility, which is largely related to Ca\(^{2+}\) content in the midpiece. Our analysis showed D2DR was present in the sperm midpiece region (Figure 1B). In in vitro experiments using Ltk-mouse fibroblasts and mouse striatal slices, stimulation of D2DR was reported to result in increasing Ca\(^{2+}\) levels. It has been reported that high concentrations of Ca\(^{2+}\) are present in the human sperm midpiece region, and the sperm neck region expresses inositol 1,4,5-trisphosphate receptor (IP3R). Dopamine treatment induces the acrosome reaction, in which elevated Ca\(^{2+}\) in spermatozoa are the major induction factor. These facts believed that dopamine may increase intracellular Ca2 levels in human sperm through D2DR, with a contribution to accelerated motility and the induction of hyperactivation. However, the present study could not reveal that the stimulation of D2DR increases intracellular Ca2 levels; whether it triggers an increase in intracellular Ca2 in human sperm needs to be further investigated.

In the seminal plasma, concentrations of dihydroxyphenylalanine (DOPA), the precursor of dopamine, are higher than in the plasma. Moreover, in patients with asthenozoospermia and oligozoospermia, the seminal plasma and blood dopamine concentrations are low compared with fertile men. During the luteal period, dopamine is present in the female fallopian tube, with a higher concentration in the isthmus region (approximately 0.32 \(\mu\)M) than in the ampulla region (approximately 0.20 \(\mu\)M). Our results show that dopamine-induced acceleration of sperm motility can be achieved by using higher dopamine concentrations (10 or 100 \(\mu\)M) than that in the semen or fallopian tube. It has been reported that human sperm motility is accelerated at dopamine concentrations close to those in the female reproductive tract.

Because the study aimed to investigate the effect of dopamine on sperm function, HSA medium was not used, which is an important component for the acceleration of sperm motility. The current study was assumed to be used in assisted reproduction technology, and sperm function was adequately induced using culture media that contained bicarbonate and HSA, which are commonly used in infertility treatment. High concentrations of dopamine further improved sperm motility. Therefore, our results show that a high concentration of dopamine may be useful to improve sperm motility in infertility treatment.

Overall, our results demonstrate that dopamine can enhance human sperm motility without elevating tyrosine phosphorylation. Moreover, this study is the first to report that sperm motility reduced after 24-h culture can be accelerated by a neurotransmitter. This may be useful to improve sperm motility in patients with

### TABLE 3 The sperm suspensions were cultured for 24 h and treated with 10 \(\mu\)M dopamine for 1 h: Analysis of several parameters of human sperm motility \((n = 10)\)

| Sperm motility parameters | Control | Dopamine 10 \(\mu\)M |
|---------------------------|---------|---------------------|
| Total motility(%)         | 79.0 (77.0–86.0) | 84.0 (80.8–92.0) |
| Progressive motility(%)   | 75.0 (69.5–81.3) | 82.5 (78.5–91.3) |
| VAP (\(\mu\)m/s)          | 30.6 (23.6–36.5) | 34.1 (32.0–36.4) |
| VCL (\(\mu\)m/s)          | 54.7 (47.8–58.1) | 60.2 (55.0–63.8)* |
| VSL (\(\mu\)m/s)          | 27.3 (20.2–33.8) | 30.0 (28.1–33.8) |
| LIN(%)                    | 50.0 (44.8–56.0) | 51.0 (44.8–56.3) |
| STR(%)                    | 82.0 (77.8–87.8) | 84.0 (82.3–88.8) |
| ALH (\(\mu\)m)           | 3.7 (2.9–4.2)    | 4.3 (3.9–4.6)*    |
| WOB(%)                    | 57.5 (53.5–64.8) | 57.0 (52.5–61.8) |
| BCF (Hz)                  | 7.4 (6.8–7.7)    | 7.4 (7.2–7.7)     |

Data are shown as the median (IQR). Asterisks denote a statistically significant difference vs. control group (p < 0.05, Wilcoxon signed-rank test).
infertility, and for successful conception either naturally or through artificial insemination.

ACKNOWLEDGMENTS
We greatly appreciate all men for their participation in this study. We would like to thank Editage (www.editage.com) for English language editing.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

HUMAN RIGHTS
All procedures followed were in accordance with the ethical standards of the Responsible Committee on Human Experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all the men who participated in the study. This study was approved by the Institutional Review Board at Tohoku University and Sendai ART Clinic.

ANIMAL STUDIES
The animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by Tohoku University.

ORCID
Kenshiro Hara https://orcid.org/0000-0001-8531-8349
Kentarou Tanemura https://orcid.org/0000-0003-4744-607X

REFERENCES
1. McLaughlan RI, de Kretser DM. Male infertility: the case for continued research. Med J Aust. 2001;174(3):116–7.
2. Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile male: a committee opinion. Fertil Steril. 2012;98(2):294–301.
3. Thonneau P, Marchand S, Tallec A, Ferrial ML, Ducot B, Lansac J, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). Hum Reprod. 1991;6(6):811–6.
4. WHO. Laboratory manual for the examination and processing of human semen. 5th ed. Geneva: World Health Organization; 2010.
5. Kao SH, Chao HT, Liu HW, Liao TL, Wei YH. Sperm mitochondrial DNA depletion in men with asthenospermia. Fertil Steril. 2004;82(1):66–73.
6. Verheyen G, Tournaye H, Staessen C, De Vos A, Vandervorst M, Van Steirteghem A. Controlled comparison of conventional in-vitro fertilization and intracytoplasmic sperm injection in patients with asthenozoospermia. Hum Reprod. 1999;14(9):2313–9.
7. Griffiths TA, Murdoch AP, Herbert M. Embryonic development in vitro is compromised by the ICSI procedure. Hum Reprod. 2000;15(7):1592–6.
8. Niu X, Long J, Gong F, Wang W. Does ICSI for in vitro fertilization cause more aneuploid embryos? Mol Cytogenet. 2020;13:27.
9. Lathi RB, Milki AA. Rate of aneuploidy in miscarriages following in vitro fertilization and Intracytoplasmic sperm injection. Fertil Steril. 2004;81(5):1270–2.
10. Austin CR. Observations on the penetration of the sperm in the mammalian egg. Aust J Sci Res B. 1951;4(4):581–96.
11. Yanagimachi R, Chang MC. Fertilization of Hamster eggs in vitro. Nature. 1963;200:281–2.
12. Ghersevich S, Massa E, Zumoffen C. Oviductal secretion and gamete interaction. Reproduction. 2015;149(1):R1-R14.
13. Jiménez-Trejo F, Tapia-Rodríguez M, Cebón M, Kuhn DM, Manjarrez-Gutiérrez G, Mendoza-Rodríguez CA, et al. Evidence of 5-HT components in human sperm: implications for protein tyrosine phosphorylation and the physiology of motility. Reproduction. 2012;144(6):677–85.
14. Bray C, Son JH, Meisel S. A nicotinic acetylcholine receptor is involved in the arsosome reaction of human sperm initiated by recombinant human ZP3. Biol Reprod. 2002;67(3):782–8.
15. Hiradate Y, Inoue H, Kobayashi N, Shirakata Y, Suzuki Y, Gotoh A, et al. Neurotensin enhances sperm capacitation and acrosome reaction in mice. Biol Reprod. 2014;91(2):53.
16. Umez U, Hiradate Y, Oikawa T, Ishiguro H, Numabe T, Hara K, et al. Exogenous neurotensin modulates sperm function in Japanese Black cattle. J Reprod Dev. 2016;62(4):409–14.
17. Kurata S, Hiradate Y, Umez U, Hara K, Tanemura K. Capacitation of mouse sperm is modulated by gamma-aminobutyric acid (GABA) concentration. J Reprod Dev. 2019;65(4):327–34.
18. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189–225.
19. Lachowicz JE, Sibley DR. Molecular characteristics of mammalian dopamine receptors. Pharmacol Toxicol. 1997;81(3):105–13.
20. Monsma FJ Jr, Mahan LC, McVittie LD, Gerfen CR, Sibley DR. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci USA. 1990;87(17):6723–7.
21. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997;17(21):8147–55.
22. Otth C, Torres M, Ramirez A, Fernandez JC, Castro M, Rauch MC, et al. Novel identification of peripheral dopaminergic D2 receptor in male germ cells. J Cell Biochem. 2007;100(1):141–50.
23. Ramirez AR, Castro MA, Angulo C, Ramíl L, Rivera MM, Torres M, et al. The presence and function of dopamine type 2 receptors in boar sperm: a possible role for dopamine in viability, capacitation, and modulation of sperm motility. Biol Reprod. 2009;80(4):753–61.
24. Keysor S, van der Horst G, Maree L. Progesterone, myo-inositol, dopamine and prolactin present in follicular fluid have differential effects on sperm motility subpopulations. Life (Basel). 2021;11(11):1250.
25. Leclerc P, de Lamirande E, Gagnon C. Cyclic adenosine 3’,5’monophosphate-dependent regulation of protein tyrosine phosphorylation in relation to human sperm capacitation and motility. Biol Reprod. 1996;55(3):684–92.
26. Visconti PE, Moore GD, Bailey JL, Leclerc P, Connors SA, Pan D, et al. Capacitation of mouse spermatozoa. II. Protein tyrosine phosphorylation and capacitation are regulated by a cAMP-dependent pathway. Development. 1995;121(4):1139–50.
27. Enjalbert A, Bockaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol. 1983;23(3):576–84.
28. Balbach M, Ghanem L, Rossetti T, Kaur N, Ritagliati C, Ferreira J, et al. Soluble adenylyl cyclase inhibition prevents human sperm functions essential for fertilization. Mol Hum Reprod. 2021;27(9):gaab054.
29. Esposito G, Jaiswal BS, Xie F, Krajnc-Franken MA, Robben TJ, Strik AM, et al. Mice deficient for soluble adenylyl cyclase are infertile because of a severe sperm-motility defect. Proc Natl Acad Sci USA. 2004;101(9):2993–8.
30. Jaiswal BS, Conti M. Calcium regulation of the soluble adenylyl cyclase expressed in mammalian spermatozoa. Proc Natl Acad Sci USA. 2003;100(19):10676–81.
31. Mortimer ST, Mortimer D. Kinematics of human spermatozoa incubated under capacitating conditions. J Androl. 1990;11(3):195–203.

32. Burkman LJ. Characterization of hyperactivated motility by human spermatozoa during capacitation: comparison of fertile and oligozoospermic sperm populations. Arch Androl. 1984;13(2–3):153–65.

33. Fakih H, MacLusky N, DeCherney A, Wallimann T, Huszar G. Enhancement of human sperm motility and velocity in vitro: effects of calcium and creatine phosphate. Fertil Steril. 1986;46(5):938–44.

34. Vallar L, Muca C, Magni M, Albert P, Bunzow J, Meldolesi J, et al. Differential coupling of dopaminergic D2 receptors expressed in different cell types. Stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis in Ltk- fibroblasts, hyperpolarization, and cytosolic-free Ca2+ concentration decrease in GH4C1 cells. J Biol Chem. 1990;265(18):10320–6.

35. Naaby-Hansen S, Wolkowicz MJ, Klotz K, Bush LA, Westbrook VA, Shibahara H, et al. Co-localization of the inositol 1,4,5-trisphosphate receptor and calreticulin in the equatorial segment and in membrane bounded vesicles in the cytoplasmic droplet of human spermatozoa. Mol Hum Reprod. 2001;7:923–33.

36. Fait G, Vered Y, Yogev L, Gamzu R, Lessing JB, Paz G, et al. High levels of catecholamines in human semen: a preliminary study. Andrologia. 2001;33(6):347–50.

37. Shukla KK, Mahdi AA, Ahmad MK, Shankhwar SN, Rajender S, Jaiswar SP. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertil Steril. 2009;92(6):1934–40.

38. Helm G, Owman C, Rosengren E, Sjöberg NO. Regional and cyclic variations in catecholamine concentration of the human fallopian tube. Biol Reprod. 1982;26(4):553–8.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Kanno H, Kurata S, Hiradate Y, Hara K, Yoshida H, Tanemura K. High concentration of dopamine treatment may induce acceleration of human sperm motility. Reprod Med Biol. 2022;21:e12482. doi: 10.1002/rmb2.12482